Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the 2 adrenergic receptor

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Almirall, S.A. patent solves the following problem:

5- (2 – {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1 (R) -hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one (Compound I) is a valiant 2 adrenoceptor agonist first disclosed in WO 2006/122788. This compound of the following chemical formula.

Our analysis of this patent is as follows:

Almirall, S.A.’s patent US 9346759 B2 deals with Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the 2 adrenergic receptor.
The present invention is directed to novel polymorphic crystalline form of a 5- (2 – {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1- (R) -hydroxyethyl) -8-hydroxyquinolin- 2 (1H) -one, heminapadisylate. invention is also directed to pharmaceutical compositions comprising said polymorphic crystalline forms, ways to use them to treat respiratory diseases associated with 2 adrenergic receptor activity and a process to prepare the polymorphic crystalline forms.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.